CIK 0001599298
- Large accelerated filer
Summit Therapeutics Inc.
Sign in to watch- Ticker
- SMMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 371979717
- Phone
- +1 305-203-2034
- Business address
- 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131
- Former names
- Summit Therapeutics plc, Summit Corp plc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-11-23 | Powell David Jonathan Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −6,987 | $1.92 | $13K | 457,699 |
| 2020-11-22 | Zanganeh Maky Chief Operating Officer | Grant or award · Stock Option (right to buy) | +2,400,000 | 3,724,499 | ||
| 2020-11-11 | Zanganeh Maky Director | Grant or award · Stock Option (right to buy) | +200,000 | 1,321,177 | ||
| 2020-11-11 | Zanganeh Maky Director | Grant or award · Stock Option (right to buy) | +3,323 | 1,324,500 | ||
| 2020-11-06 | DUGGAN ROBERT W Chief Executive Officer | Purchase | +14,071,856 | $3.34 | $47.0M | 56,296,533 |
| 2020-10-04 | Graham Camilla Chief Clinical Affairs Officer | Grant or award · Stock Option (right to buy) | +400,000 | $3.34 | $1.3M | 400,000 |
| 2020-10-02 | DUGGAN ROBERT W Chief Executive Officer | Grant or award · Common Stock | +9,730,539 | 9,730,539 |
Page 10 of 10 · 187 trades